FibroBiologics, Inc. (FBLG) stock
Close on Nov 12, 2026Market cap $6.44MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $6.44M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.39
- Dividend yield
- –
- Free cash flow yield
- -229.62%
Fundamentals
- Net income
- -$18.14M
- EPS, diluted
- -$5.67
- Free cash flow
- -$14.80M
- Book value per share
- $0.74
- Diluted shares
- 6M
Trading
- Previous close
- $1.00
- Open
- $1.01
- Day's range
- $0.93 – $1.01
- Volume
- 64,515
- Average volume (20 days)
- 85,628
- Beta (5 years)
- 0.40
- 52-week range
- $0.62 – $9.60
- RSI (14 days)
- 47.3
- Volatility (1 year)
- 128.5%
- Relative volume
- 0.31×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | FBLG | S&P 500 | Difference | FBLG per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.2% | -2.7% | −0.5 pts | ||
| 3 months | -12.8% | -1.7% | −11.1 pts | ||
| Year to date | -78.5% | +11.9% | −90.4 pts | ||
| 1 year | -85.3% | +12.0% | −97.2 pts |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases FibroBiologics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About FibroBiologics
Pharmaceutical Preparations
FibroBiologics, Inc. is a clinical-stage biotechnology company that develops and commercializes fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company's platform utilizes human dermal fibroblasts to create biological therapies across clinical target areas such as wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications, including thymic involution reversal. Its primary therapeutic product candidates include CYWC628 for wound care, CYPS317 for psoriasis, CYMS101 for multiple sclerosis, and CybroCell for degenerative disc disease, targeting chronic patient populations such as those with diabetic foot ulcers.
Company profile, executives and historyFibroBiologics stock: common questions
What is FibroBiologics's stock price?
FBLG closed at $0.97 on Nov 12, 2026, down 2.81% on the day. Over the past 52 weeks it traded between $0.62 and $9.60.
What is FibroBiologics's market cap?
FibroBiologics was worth $6.44M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is FBLG's P/E ratio?
FibroBiologics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$5.67), so it has no meaningful P/E ratio.
Does FibroBiologics pay a dividend?
No. FibroBiologics has not paid a cash dividend over the last twelve months.
How has FBLG stock performed over the past year?
Including dividends, FBLG returned -85.3% over the past year, against +12.0% for the S&P 500.
Who are FibroBiologics's competitors?
Companies most similar to FibroBiologics by business, industry and size include EVMN, VICP, LGVN, ABEO, HCWB.
See a number that looks wrong?